U.S.-based Biomarin Pharmaceutical Inc.’s treatment for one of the most common forms of dwarfism received clearance from the European Commission, becoming the first therapy to get an approval in the region for achondroplasia.

Med Ad News talked to Wendbush Securities analysts David Nierengarten, Laura Chico, and Liana Moussatos about various new drug approvals and other recent news updates in the industry. 

Pfizer announced plans to buy Therachon, a rare disease biotech company based in Basel, Switzerland.

Palo Alto, Calif.-based BridgeBio Pharma is launching a new spinout to develop a recently abandoned Novartis cancer treatment now in its possession.